Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

被引：1
|
作者：
Shustov, Andrei R.
Coiffier, Bertrand
Horwitz, Steven M.
Sokol, Lubomir
Pro, Barbara
Nielsen, Tina
Wolfson, Julie
Balser, Barbara E.
Eisch, Robin
Popplewell, Leslie
Prince, Miles
Allen, Steven L.
Piekarz, Richard
Bates, Susan E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis
    Abdulsattar, Waleed
    Beran, Azizullah
    Alqahtani, Ali
    Abuhelwa, Ziad
    Mhanna, Mohammed
    Alloghbi, Abdurahman
    Srour, Omar
    Ayesh, Hazem
    Hamouda, Danae
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (05) : E589 - E592
  • [22] Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
    Woo, Sukyung
    Gardner, Erin R.
    Chen, Xiaohong
    Ockers, Sandra B.
    Baum, Caitlin E.
    Sissung, Tristan M.
    Price, Douglas K.
    Frye, Robin
    Piekarz, Richard L.
    Bates, Susan E.
    Figg, William D.
    CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1496 - 1503
  • [23] Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    Piekarz, Richard L.
    Frye, Robin
    Prince, H. Miles
    Kirschbaum, Mark H.
    Zain, Jasmine
    Allen, Steven L.
    Jaffe, Elaine S.
    Ling, Alexander
    Turner, Maria
    Peer, Cody J.
    Figg, William D.
    Steinberg, Seth M.
    Smith, Sonali
    Joske, David
    Lewis, Ian
    Hutchins, Laura
    Craig, Michael
    Fojo, A. Tito
    Wright, John J.
    Bates, Susan E.
    BLOOD, 2011, 117 (22) : 5827 - 5834
  • [24] A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Strati, Paolo
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis E.
    Fowler, Nathan
    Nastoupil, Loretta
    Romaguera, Jorge E.
    Samaniego, Felipe
    Garg, Naveen
    Feng, Lei
    Wesson, Emily T.
    Ruben, Charnelle E.
    Stafford, Mildred D.
    Nieto, Yago
    Khouri, Issa F.
    Hosing, Chitra
    Horowitz, Sandra B.
    T-Kamble, Rammurti
    Fanale, Michelle A.
    HAEMATOLOGICA, 2018, 103 (09) : E416 - E418
  • [25] The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
    Horwitz, Steven M.
    Soto, Jasminder
    Youssoufian, Hagop
    Lloyd, Deborah
    Le, Ngocdiep T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)
    Goh, Yeow-Tee
    Hwang, William Y. K.
    Diong, Colin Phipps
    Hsien, Yap Chun
    Tay, Kevin
    Lim, Soon Thye
    Lee, Yuh Shan
    Ng, Soo Chin
    Fadilah, S.
    Kim, Won Seog
    Tan, Daryl
    BLOOD, 2014, 124 (21)
  • [27] Lack of Response to Romidepsin in Children with Relapsed / Refractory Peripheral T -Cell Lymphoma (PTCL): A Single Centre Experience
    Tandon, S.
    Bartram, J.
    Punnett, A.
    Hitzler, J.
    Davidson, S.
    Villani, A.
    Shlien, A.
    Malkin, D.
    Abla, O.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S271 - S272
  • [28] Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Bartlett, Nancy L.
    Assouline, Sarit
    Schuster, Stephen J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin, Shen
    Doral, Michelle Y.
    Sit, Jason
    Chen, Vivian
    Huang, Huang
    Zhou, Mingzhu
    Wei, Michael C.
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S455
  • [29] All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
    Fante, Matthias A.
    Harrer, Dennis C.
    Zartner, Barbara
    Lueke, Florian
    Mayer, Stephanie
    Menhart, Karin
    Reichle, Albrecht
    Herr, Wolfgang
    Vogelhuber, Martin
    Heudobler, Daniel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] PRALATREXATE REVERSES THE TREND TO PROGRESSIVE RESISTANCE IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)
    Coiffier, B.
    Zinzani, P.
    Koutsoukos, A.
    O'Connor, O.
    ANNALS OF ONCOLOGY, 2011, 22 : 202 - 202
12345